Sonnet BioTherapeutics entered into a license agreement with Alkem Laboratories for the development and commercialization of SON-080, a treatment for diabetic peripheral neuropathy, with an upfront payment of $1 million and potential milestone payments of up to $1 million, plus royalties on net sales.